{"filing":{"accession_number":"0001140361-26-032014","cik":"0001723128","ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"ef20079825_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1723128/000114036126032014/ef20079825_8k.htm"},"events":[{"id":26538,"run_id":24122,"accession_number":"0001140361-26-032014","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences, creating a fully integrated global biosimilars leader and extending the company's growth profile into the 2030s with access to a $300+ billion global biologics market. The transaction was funded through $350 million in incremental financing under Amendment No. 4 to the Term Loan Credit Agreement, and Kashiv shareholders received 28,942,098 shares of Amneal Class A Common Stock as consideration.","company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27693,"accession_number":"0001140361-26-032014","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Item 1.01 discloses the completion of Amneal's acquisition of Kashiv BioSciences, a material transaction creating \"a fully integrated global biosimilars leader\" and extending \"growth profile into the 2030s.\" The filing also documents two definitive agreements entered into in connection with the acquisition: a First Amendment to the Stockholders Agreement and Amendment No. 4 to the Term Loan Credit Agreement providing $350 million in incremental financing for the acquisition consideration. This is a classic M\u0026A completion disclosure under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:10:55.968202+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27694,"accession_number":"0001140361-26-032014","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses the completion of Amneal's acquisition of Kashiv BioSciences, creating an integrated global biosimilars platform. The press release explicitly states \"Amneal Pharmaceuticals, Inc. today announced the completion of its acquisition of Kashiv BioSciences, LLC,\" establishing this as a material acquisition that extends Amneal's growth profile into the 2030s and provides access to a $300+ billion global biologics market. This is a classic Item 2.01 material acquisition completion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:10:55.968202+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27695,"accession_number":"0001140361-26-032014","item_number":"2.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.03 incorporates by reference Item 1.01, which covers material acquisitions. The press release announces completion of Amneal's acquisition of Kashiv BioSciences, creating an integrated global biosimilars platform. This is a material M\u0026A transaction that extends Amneal's growth profile into the 2030s and provides access to a $300+ billion global biologics market, directly affecting the registrant's strategic direction and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:10:55.968202+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27696,"accession_number":"0001140361-26-032014","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"reasoning":"Item 3.02 discloses an unregistered issuance of 28,942,098 shares of Class A Common Stock to the sellers of Kashiv BioSciences as consideration in a completed acquisition. While the issuance itself is unregistered and dilutive, the primary event is the completion of the Kashiv acquisition—a material M\u0026A transaction. The stock issuance is the consideration mechanism, not the principal event. However, Item 3.02 specifically governs unregistered equity sales, and the filing emphasizes the share issuance details and registration statement obligations, suggesting the filer classified this as a dilutive issuance disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:10:55.968202+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27697,"accession_number":"0001140361-26-032014","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses completion of Amneal's acquisition of Kashiv BioSciences, creating an integrated global biosimilars platform. The press release emphasizes this as a \"pivotal step\" in Amneal's strategy, extending growth into the next decade and providing access to a $300+ billion global biologics market. This is a material M\u0026A completion that would significantly affect investor assessment of the company's strategic direction and growth prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:10:55.968202+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27693,"accession_number":"0001140361-26-032014","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Item 1.01 discloses the completion of Amneal's acquisition of Kashiv BioSciences, a material transaction creating \"a fully integrated global biosimilars leader\" and extending \"growth profile into the 2030s.\" The filing also documents two definitive agreements entered into in connection with the acquisition: a First Amendment to the Stockholders Agreement and Amendment No. 4 to the Term Loan Credit Agreement providing $350 million in incremental financing for the acquisition consideration. This is a classic M\u0026A completion disclosure under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:10:55.968202+00:00","company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","filing_date":"2026-08-10"},{"id":27694,"accession_number":"0001140361-26-032014","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses the completion of Amneal's acquisition of Kashiv BioSciences, creating an integrated global biosimilars platform. The press release explicitly states \"Amneal Pharmaceuticals, Inc. today announced the completion of its acquisition of Kashiv BioSciences, LLC,\" establishing this as a material acquisition that extends Amneal's growth profile into the 2030s and provides access to a $300+ billion global biologics market. This is a classic Item 2.01 material acquisition completion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:10:55.968202+00:00","company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","filing_date":"2026-08-10"},{"id":27695,"accession_number":"0001140361-26-032014","item_number":"2.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.03 incorporates by reference Item 1.01, which covers material acquisitions. The press release announces completion of Amneal's acquisition of Kashiv BioSciences, creating an integrated global biosimilars platform. This is a material M\u0026A transaction that extends Amneal's growth profile into the 2030s and provides access to a $300+ billion global biologics market, directly affecting the registrant's strategic direction and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:10:55.968202+00:00","company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","filing_date":"2026-08-10"},{"id":27696,"accession_number":"0001140361-26-032014","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"reasoning":"Item 3.02 discloses an unregistered issuance of 28,942,098 shares of Class A Common Stock to the sellers of Kashiv BioSciences as consideration in a completed acquisition. While the issuance itself is unregistered and dilutive, the primary event is the completion of the Kashiv acquisition—a material M\u0026A transaction. The stock issuance is the consideration mechanism, not the principal event. However, Item 3.02 specifically governs unregistered equity sales, and the filing emphasizes the share issuance details and registration statement obligations, suggesting the filer classified this as a dilutive issuance disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:10:55.968202+00:00","company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","filing_date":"2026-08-10"},{"id":27697,"accession_number":"0001140361-26-032014","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses completion of Amneal's acquisition of Kashiv BioSciences, creating an integrated global biosimilars platform. The press release emphasizes this as a \"pivotal step\" in Amneal's strategy, extending growth into the next decade and providing access to a $300+ billion global biologics market. This is a material M\u0026A completion that would significantly affect investor assessment of the company's strategic direction and growth prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:10:55.968202+00:00","company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","filing_date":"2026-08-10"}]}